CRDF vs NBIX · rev $145.0K vs P/E 45, rev $1.77B
Cardiff Oncology Inc (CRDF) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Cardiff Oncology Inc (CRDF) is a biotechnology company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported CRDF revenue for 2026-06-30 was $145.0K. Net income was -$21.6M. CRDF currently screens at market cap $238.8M.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
CRDF currently screens at market cap $238.8M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the CRDF and NBIX stock pages for the full models.
Not investment advice.